The number of lawsuits against Merck over its withdrawn painkiller Vioxx has increased substantially over the past two months, with the company now facing more than 6,500 suits. Lawyers say some of the new cases were triggered by Merck's loss in the first case to go to trial, but a company spokesman said the new filings "are not unexpected and do not change our strategy."

Related Summaries